| VLST Corporation discovers and develops novel therapeutics for the treatment of inflammatory and autoimmune diseases. Disease areas in which the company’s technology may have utility include multiple sclerosis, lupus, cardiovascular disease, diabetes and obesity. The company has already identified eight novel disease targets and is currently evaluating three of these targets for their therapeutic potential in relevant preclinical disease models.
The company was co-founded by Drs. Craig Smith and Steven Wiley. Dr. Smith and Dr. Ray Goodwin, a member of the VLST scientific advisory board, are co-inventors of Enbrel, a biologic therapy for the treatment of several inflammatory disorders.
|
